Pimecrolimus 1% cream for pruritus in postmenopausal diabetic women with vulvar lichen simplex chronicus: A prospective non-controlled case series

Basit Öğe Kaydı
dc.authoridOzdemir, Orcun/0009-0006-4540-0835
dc.authorwosidYilmaz, Bulent/HKE-5048-2023
dc.authorwosidYilmaz, Bulent/GPK-8613-2022
dc.contributor.authorKelekci, Handan Kiymet
dc.contributor.authorUncu, Hikmet Gulsen
dc.contributor.authorYilmaz, Bulent
dc.contributor.authorOzdemir, Orcun
dc.contributor.authorSut, Necdet
dc.contributor.authorKelekci, Sefa
dc.date.accessioned2024-06-12T11:07:38Z
dc.date.available2024-06-12T11:07:38Z
dc.date.issued2008
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: Pruritus vulvae may have a variety of causes, such as infections, dermatologic disorders or non-neoplastic/neoplastic vulvar diseases. Objectives: To investigate the efficacy and side effects of topical pimecrolimus 1% cream for pruritus vulvae. Methods: Twelve postmenopausal diabetic women with vulvar lichen simplex chronicus were enrolled in this trial. Each patient was treated with pimecrolimus 1% cream which was applied twice daily in a thin layer to the vulvae for 3 months. Clinical examination and recording of patients' symptoms using a scoring system was performed by the same physician before, after 4 weeks and after 3 months of therapy. Results: All of the patients completed the study. A substantial decrease in pruritus after treatment was reported by the patients at the 4th week (2.17 +/- 0.72, p < 0.01) and 3rd month of treatment (0.42 +/- 0.92, p < 0.001) when compared with the baseline score (3.75 +/- 0.45). Follow-up of the patients after 3 months of treatment showed that complete cure occurred in 10 patients (83.3%) and the pruritus was improved in two (16.7%) patients. Conclusions: Pimecrolimus 1% cream seems to be an effective and safe treatment modality for pruritus in postmenopausal women with vulvar lichen simplex chronicus.en_US
dc.identifier.doi10.1080/09546630801955341
dc.identifier.endpage278en_US
dc.identifier.issn0954-6634
dc.identifier.issn1471-1753
dc.identifier.issue5en_US
dc.identifier.pmid19160532en_US
dc.identifier.scopus2-s2.0-51049105267en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage274en_US
dc.identifier.urihttps://doi.org/10.1080/09546630801955341
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22119
dc.identifier.volume19en_US
dc.identifier.wosWOS:000258899100004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal Of Dermatological Treatmenten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLichen Simplex Chronicusen_US
dc.subjectPimecrolimus 1% Creamen_US
dc.subjectPostmenopausalen_US
dc.subjectVulvar Pruritusen_US
dc.subjectEpidermal Langerhans Cellsen_US
dc.subjectAtopic-Dermatitisen_US
dc.subjectTopical Pimecrolimusen_US
dc.subjectTacrolimusen_US
dc.subjectCorticosteroidsen_US
dc.subjectEfficacyen_US
dc.subjectSkinen_US
dc.titlePimecrolimus 1% cream for pruritus in postmenopausal diabetic women with vulvar lichen simplex chronicus: A prospective non-controlled case seriesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu